

Alessio Cortellini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2974124/publications.pdf>

Version: 2024-02-01

159
papers

4,048
citations

159525

30
h-index

189801

50
g-index

164
all docs

164
docs citations

164
times ranked

5236
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 865-874.	2.0	11
2	Time-Dependent COVID-19 Mortality in Patients With Cancer. <i>JAMA Oncology</i> , 2022, 8, 114.	3.4	50
3	Association between immune-related adverse event timing and treatment outcomes. <i>Oncolmmunology</i> , 2022, 11, 2017162.	2.1	33
4	High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status. <i>Journal of Hematology and Oncology</i> , 2022, 15, 9.	6.9	5
5	New Frontiers in the Medical Therapy of Hepatocellular Carcinoma. <i>Chemotherapy</i> , 2022, 67, 164-172.	0.8	10
6	A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry. <i>Journal of Thoracic Oncology</i> , 2022, 17, 661-674.	0.5	9
7	One more piece to SOLIDify our knowledge on the impact of SARS-CoV-2 in patients with cancer. <i>Translational Lung Cancer Research</i> , 2022, 11, 132-134.	1.3	1
8	Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations. , 2022, 10, e004374.		13
9	Predictive biomarkers of response to immune checkpoint inhibitors in hepatocellular carcinoma. <i>Expert Review of Molecular Diagnostics</i> , 2022, 22, 253-264.	1.5	20
10	Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Childâ€Pugh A and B cirrhosis: A realâ€world study. <i>Hepatology</i> , 2022, 76, 1000-1012.	3.6	114
11	Systemic therapy for pre-treated malignant mesothelioma: A systematic review, meta-analysis and network meta-analysis of randomised controlled trials. <i>European Journal of Cancer</i> , 2022, 166, 287-299.	1.3	7
12	The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 186.	1.7	44
13	Host immuneâ€inflammatory markers to unravel the heterogeneous outcome and assessment of patients with <sc>PDâ€L1</sc> â‰¥50% metastatic nonâ€small cell lung cancer and poor performance status receiving firstâ€line immunotherapy. <i>Thoracic Cancer</i> , 2022, 13, 483-488.	0.8	7
14	COVID-19 Sequelae and the Host Proinflammatory Response: An Analysis From the OnCovid Registry. <i>Journal of the National Cancer Institute</i> , 2022, 114, 979-987.	3.0	14
15	Persistence of long-term COVID-19 sequelae in patients with cancer: An analysis from the OnCovid registry. <i>European Journal of Cancer</i> , 2022, 170, 10-16.	1.3	11
16	Osimertinib as induction therapy for oligometastatic non-small cell lung cancer with EGFR mutation: a case report. <i>Translational Lung Cancer Research</i> , 2022, 11, 686-696.	1.3	1
17	Novel immunotherapy combinations in clinical trials for hepatocellular carcinoma: will they shape the future treatment landscape?. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 681-691.	1.9	7
18	Coronavirus Disease 2019 Outcomes, Patient Vaccination Status, and Cancer-Related Delays During the Omicron Wave: A Brief Report From the TERAVOLT Analysis. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100335.	0.6	7

#	ARTICLE	IF	CITATIONS
19	Antibiotic Exposure and Immune Checkpoint Inhibitors in Patients With NSCLC: The Backbone Matters. <i>Journal of Thoracic Oncology</i> , 2022, 17, 739-741.	0.5	4
20	Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer. <i>European Journal of Cancer</i> , 2022, 171, 64-74.	1.3	19
21	Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study. <i>Lancet Oncology</i> , The, 2022, 23, 865-875.	5.1	50
22	Clinical assessment of the Omicron outbreak in Europe and trends in morbidity and mortality from COVID-19 and cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, e18673-e18673.	0.8	1
23	A phase Ib study of pembrolizumab following trans-arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): PETAL.. <i>Journal of Clinical Oncology</i> , 2022, 40, e16195-e16195.	0.8	3
24	The prognostic role of nephrectomy in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with immunotherapy according to the novel prognostic Meet-URO score: Subanalysis of the Meet-URO 15 study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4535-4535.	0.8	0
25	Anthracycline-Free Neoadjuvant Treatment in Patients with HER2-Positive Breast Cancer: Real-Life Use of Pertuzumab, Trastuzumab and Taxanes Association with an Exploratory Analysis of PIK3CA Mutational Status. <i>Cancers</i> , 2022, 14, 3003.	1.7	3
26	Digital quantification of lymphocytic infiltration on routine H&E images and immunotherapy response in non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9066-9066.	0.8	1
27	Differential prognostic effect of systemic inflammation in patients with non-small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 OAK trial. <i>Cancer</i> , 2022, 128, 3067-3079.	2.0	15
28	Differential prognostic effect of systemic inflammation in patients with NSCLC treated with immunotherapy or chemotherapy: A post hoc analysis of the phase III OAK trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9056-9056.	0.8	1
29	Artificial intelligence in digital pathology approach identifies the predictive impact of tertiary lymphoid structures with immune-checkpoints therapy in NSCLC.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9065-9065.	0.8	4
30	Clinical effectiveness of SARS-CoV-2 vaccines and booster doses in patients with cancer: An analysis from the European OnCovid registry.. <i>Journal of Clinical Oncology</i> , 2022, 40, e18725-e18725.	0.8	0
31	Antibiotic therapy and association with oncological outcomes from targeted and immune-based therapy in hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 4089-4089.	0.8	2
32	Preliminary results from a phase Ib study of neoadjuvant ipilimumab plus nivolumab prior to liver resection for hepatocellular carcinoma: The PRIME-HCC trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4093-4093.	0.8	6
33	Comparative efficacy of novel combination immunotherapy strategies for unresectable hepatocellular carcinoma (HCC): A network meta-analysis of landmark phase III trials.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4098-4098.	0.8	0
34	Efficacy outcomes and prognostic factors from real-world patients with advanced non-small-cell lung cancer treated with first-line chemoimmunotherapy: The Spinnaker retrospective study. <i>International Immunopharmacology</i> , 2022, 110, 108985.	1.7	14
35	Antibiotic-dependent effect of probiotics in patients with non-small cell lung cancer treated with PD-1 checkpoint blockade. <i>European Journal of Cancer</i> , 2022, 172, 199-208.	1.3	9
36	Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index. <i>European Journal of Cancer</i> , 2021, 142, 18-28.	1.3	81

#	ARTICLE	IF	CITATIONS
37	Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study). <i>Clinical Medicine Insights: Oncology</i> , 2021, 15, 117955492110216.	0.6	12
38	A Comparison Between First-, Second- and Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non-Small-Cell Lung Cancer and Brain Metastases. <i>Journal of Molecular Pathology</i> , 2021, 2, 1-10.	0.5	5
39	The interplay between cholesterol (and other metabolic conditions) and immune-checkpoint immunotherapy: shifting the concept from the "inflamed tumor" to the "inflamed patient". <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 1930-1934.	1.4	10
40	Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: A case-control matched analysis from a large multicenter study. <i>Thoracic Cancer</i> , 2021, 12, 880-889.	0.8	30
41	The Gustave Roussy Immune (GRIm)-Score Variation Is an Early-on-Treatment Biomarker of Outcome in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Pembrolizumab. <i>Journal of Clinical Medicine</i> , 2021, 10, 1005.	1.0	23
42	Into the storms: Organising oncological home care services during natural disasters and global pandemics. <i>European Journal of Cancer Care</i> , 2021, 30, e13433.	0.7	1
43	PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma. <i>BMC Cancer</i> , 2021, 21, 301.	1.1	42
44	Association of Obesity With Survival Outcomes in Patients With Cancer. <i>JAMA Network Open</i> , 2021, 4, e213520.	2.8	197
45	Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy. , 2021, 9, e002421.		80
46	The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 \geq 50% advanced non-small-cell lung cancer. <i>ESMO Open</i> , 2021, 6, 100078.	2.0	35
47	Targeting KRAS in Solid Tumors: Current Challenges and Future Opportunities of Novel KRAS Inhibitors. <i>Pharmaceutics</i> , 2021, 13, 653.	2.0	33
48	Treatment-related toxicity and improved outcomes with immune checkpoint inhibitors in patients with hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4085-4085.	0.8	0
49	Determinants of enhanced vulnerability to Covid-19 in U.K. cancer patients: Results from the OnCovid study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 1574-1574.	0.8	1
50	Post-progression outcomes of NSCLC patients with PD-L1 expression \geq 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study. <i>European Journal of Cancer</i> , 2021, 148, 24-35.	1.3	19
51	Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy. <i>European Journal of Cancer</i> , 2021, 150, 224-231.	1.3	24
52	The systemic pro-inflammatory response: targeting the dangerous liaison between COVID-19 and cancer. <i>ESMO Open</i> , 2021, 6, 100123.	2.0	10
53	Knowledge and attitudes of Italian medical oncologists and palliative care physicians toward medical use of cannabis in cancer care: a national survey. <i>Supportive Care in Cancer</i> , 2021, 29, 7845-7854.	1.0	7
54	PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort. <i>Journal of Translational Medicine</i> , 2021, 19, 270.	1.8	14

#	ARTICLE	IF	CITATIONS
55	Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: a European study. <i>European Journal of Cancer</i> , 2021, 150, 190-202.	1.3	37
56	Clinicians'™ Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, 'œReal-Life' Case-Control Study. <i>Clinical Colorectal Cancer</i> , 2021, , .	1.0	8
57	Therapeutic targeting of VEGFR2 in HBV-associated hepatocellular carcinoma. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 515-516.	3.7	1
58	Clinical determinants of complete response to vismodegib in locally advanced basal cell carcinoma: a multicentre experience. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e923-e926.	1.3	2
59	PD-1 Blockade for Hepatocellular Carcinoma: Current Research and Future Prospects. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 887-897.	1.8	17
60	Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy. <i>Annals of Oncology</i> , 2021, 32, 1391-1399.	0.6	32
61	Immunotherapy in Hepatocellular Carcinoma. <i>Current Treatment Options in Oncology</i> , 2021, 22, 87.	1.3	25
62	Response to letter entitled: Re: Predictive ability of a drug-based score in advanced non-small cell lung cancer patients receiving first-line immunotherapy. <i>European Journal of Cancer</i> , 2021, 155, 315-316.	1.3	1
63	Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice. <i>European Journal of Cancer</i> , 2021, 157, 140-152.	1.3	42
64	Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma. <i>European Journal of Cancer</i> , 2021, 157, 250-258.	1.3	52
65	Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study). <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110196.	1.4	36
66	Combined PD-1/VEGFR Blockade: A New Era of Treatment for Hepatocellular Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 908-910.	3.2	11
67	GU-CA-COVID: a clinical audit among Italian genitourinary oncologists during the first COVID-19 outbreak. <i>Therapeutic Advances in Urology</i> , 2021, 13, 175628722110543.	0.9	3
68	Early Antibiotic Exposure Is Not Detrimental to Therapeutic Effect from Immunotherapy in Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2021, 10, 583-592.	4.2	33
69	Post-Induction Management in Patients With Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Doublet Regimens: A Multicentre Study. <i>Frontiers in Oncology</i> , 2021, 11, 712053.	1.3	5
70	Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer. <i>JAMA Oncology</i> , 2021, 7, 1856.	3.4	74
71	Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study. <i>Lancet Oncology</i> , The, 2021, 22, 1669-1680.	5.1	73
72	A multicenter study of skin toxicity management in patients with left-sided, RAS/BRAF wild-type metastatic colorectal cancer treated with first-line anti-EGFR-based doublet regimen: is there room for improvement?. <i>Supportive Care in Cancer</i> , 2021, 30, 2455.	1.0	1

#	ARTICLE	IF	CITATIONS
73	COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110534.	1.4	5
74	First-line carboplatin/nab-paclitaxel in advanced ovarian cancer patients, after hypersensitivity reaction to solvent-based taxanes: a single-institution experience. <i>Clinical and Translational Oncology</i> , 2020, 22, 158-162.	1.2	15
75	Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians' attitudes. <i>Clinical and Translational Oncology</i> , 2020, 22, 844-851.	1.2	21
76	Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer. <i>Clinical and Translational Oncology</i> , 2020, 22, 708-716.	1.2	6
77	The PERSONS score: A new tool for cancer patients' symptom assessment in simultaneous care and home care settings. <i>Palliative and Supportive Care</i> , 2020, 18, 33-38.	0.6	4
78	Unlocking the secret of the obesity paradox in renal tumours. <i>Lancet Oncology</i> , The, 2020, 21, 194-196.	5.1	13
79	Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression $\geq 50\%$: a multicenter study with external validation. , 2020, 8, e001403.		57
80	Supporting Clinical Decision-Making during the SARS-CoV-2 Pandemic through a Global Research Commitment: The TERA-VOLT Experience. <i>Cancer Cell</i> , 2020, 38, 602-604.	7.7	6
81	An Italian Retrospective Survey on Bone Metastasis in Melanoma: Impact of Immunotherapy and Radiotherapy on Survival. <i>Frontiers in Oncology</i> , 2020, 10, 1652.	1.3	10
82	Letter to the Editor: considerations about recent findings on long-term adverse events of PD-1/PD-L1 checkpoint inhibitors. <i>European Journal of Cancer</i> , 2020, 139, 41-42.	1.3	0
83	Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592096846.	1.4	14
84	Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study. <i>Lung Cancer</i> , 2020, 150, 123-131.	0.9	13
85	Evaluation of Prognostic Factors for Survival in Transverse Colon Cancer. <i>Cancers</i> , 2020, 12, 2457.	1.7	3
86	Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice. , 2020, 8, e001361.		126
87	The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with Immunotherapy. <i>Vaccines</i> , 2020, 8, 203.	2.1	38
88	TERA-VOLT: Thoracic Cancers International COVID-19 Collaboration. <i>Cancer Cell</i> , 2020, 37, 742-745.	7.7	51
89	Evaluation of Second-Line Anti-VEGF after First-Line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter "SLAVE" Study. <i>Cancers</i> , 2020, 12, 1259.	1.7	19
90	The treatment paradigm of right-sided metastatic colon cancer: harboring BRAF mutation makes the difference. <i>International Journal of Colorectal Disease</i> , 2020, 35, 1513-1527.	1.0	7

#	ARTICLE	IF	CITATIONS
91	Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of $\geq 50\%$. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 2209-2221.	2.0	60
92	COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. <i>Lancet Oncology</i> , The, 2020, 21, 914-922.	5.1	503
93	Rare bone toxicity associated with vismodegib. <i>JAAD Case Reports</i> , 2020, 6, 482-485.	0.4	1
94	Correlation Between Immune-related Adverse Event (IRAE) Occurrence and Clinical Outcome in Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Nivolumab: IRAENE Trial, an Italian Multi-institutional Retrospective Study. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 477-488.	0.9	15
95	Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression $\geq 50\%$ and Their Relationship With Clinical Outcomes. <i>Clinical Lung Cancer</i> , 2020, 21, 498-508.e2.	1.1	50
96	Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDia study. <i>Immunotherapy</i> , 2020, 12, 151-159.	1.0	16
97	Haloperidol for the treatment of opioid addiction in advanced cancer patients: a case series. <i>Journal of Addictive Diseases</i> , 2020, 38, 229-234.	0.8	4
98	Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events. <i>European Journal of Cancer</i> , 2020, 128, 17-26.	1.3	85
99	COVID-19 pneumonia and immune-related pneumonitis: critical issues on differential diagnosis, potential interactions, and management. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 959-964.	1.4	18
100	Family History of Cancer as Potential Prognostic Factor in Stage III Colorectal Cancer: a Retrospective Monoinstitutional Study. <i>Journal of Gastrointestinal Cancer</i> , 2020, 51, 1094-1101.	0.6	2
101	Tryptophan Catabolism as Immune Mechanism of Primary Resistance to Anti-PD-1. <i>Frontiers in Immunology</i> , 2020, 11, 1243.	2.2	30
102	Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 319-326.	1.4	12
103	Immunological insights on influenza infection and vaccination during immune checkpoint blockade in cancer patients. <i>Immunotherapy</i> , 2020, 12, 105-110.	1.0	33
104	Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: a multicenter real-life study. <i>Scientific Reports</i> , 2020, 10, 1456.	1.6	64
105	Anti-PD1 antibodies in patients aged ≥ 75 years with metastatic melanoma: A retrospective multicentre study. <i>Journal of Geriatric Oncology</i> , 2020, 11, 515-522.	0.5	31
106	Evaluating the role of FAMILY history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study. <i>Oncolmmunology</i> , 2020, 9, 1710389.	2.1	9
107	Status of correlation between BMI and response to immunocheck-point inhibitor in advanced non-small-cell lung cancer. <i>Lung Cancer Management</i> , 2020, 9, LMT26.	1.5	9
108	Home Care for Cancer Patients During COVID-19 Pandemic: The Double Triage Protocol. <i>Journal of Pain and Symptom Management</i> , 2020, 60, e5-e7.	0.6	45

#	ARTICLE	IF	CITATIONS
109	The Impact of Locoregional Treatment on Response to Nivolumab in Advanced Platinum Refractory Head and Neck Cancer: The Need Trial. <i>Vaccines</i> , 2020, 8, 191.	2.1	10
110	Expression of pro-angiogenic factors as potential biomarkers in experimental models of colon cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 1427-1440.	1.2	10
111	Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study. <i>European Journal of Cancer</i> , 2020, 134, 19-28.	1.3	45
112	Palliative radiotherapy in advanced cancer patients treated with immune-checkpoint inhibitors: The PRACTICE study. <i>Biomedical Reports</i> , 2020, 12, 59-67.	0.9	9
113	Are anti-PD1 and anti-PD-L1 alike? The non-small-cell lung cancer paradigm. <i>Oncology Reviews</i> , 2020, 14, 490.	0.8	36
114	The Promising Link Among Tumor Mutational Burden, Immune-Related Adverse Events, and Immune Checkpoint Inhibitors Efficacy in SCLC. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100080.	0.6	1
115	A reflection on the actual place of osimertinib in the treatment algorithm of EGFR-positive non-small cell lung cancer patients. <i>Journal of Thoracic Disease</i> , 2020, 12, 6107-6111.	0.6	1
116	A reflection on the actual place of osimertinib in the treatment algorithm of EGFR-positive non-small cell lung cancer patients. <i>Journal of Thoracic Disease</i> , 2020, 12, 6107-6111.	0.6	2
117	The PERSONS score for symptoms assessment in simultaneous care setting: A pilot study. <i>Palliative and Supportive Care</i> , 2019, 17, 82-86.	0.6	4
118	A real-life multicenter study on body weight loss and body mass index in advanced Gastric Cancer patients treated with Ramucirumab-based second-line therapy. <i>Annals of Oncology</i> , 2019, 30, iv27.	0.6	0
119	Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 2365-2373.	1.2	9
120	Cancer Care After Natural Disaster: Different Countries, Similar Problems. <i>Journal of Global Oncology</i> , 2019, 5, 1-2.	0.5	7
121	Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patients. <i>Scientific Reports</i> , 2019, 9, 13218.	1.6	14
122	Looking for A Place for Dose-Dense TMZ Regimens in GBM Patients: An Experience with MGMT Exploratory Evaluation. <i>Bioengineering</i> , 2019, 6, 11.	1.6	2
123	<p>Weekly alternate intensive regimen FlrB/FOx in metastatic colorectal cancer patients: an update from clinical practice</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 2159-2170.	1.0	8
124	What cancer patients actually know regarding medical cannabis? A cross-sectional survey with a critical analysis of the current attitudes. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 1439-1444.	0.5	9
125	Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study. <i>Oncologist</i> , 2019, 24, e327-e337.	1.9	131
126	A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable. , 2019, 7, 57.		275

#	ARTICLE	IF	CITATIONS
127	Safe Administration of anti-PD-L1 Atezolizumab in a Patient with Metastatic Urothelial Cell Carcinoma and End-Stage Renal Disease on Dialysis. <i>Case Reports in Oncological Medicine</i> , 2019, 2019, 1-3.	0.2	8
128	Notch pathway in small-cell lung cancer: from preclinical evidence to therapeutic challenges. <i>Cellular Oncology (Dordrecht)</i> , 2019, 42, 261-273.	2.1	45
129	Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients. <i>Clinical Lung Cancer</i> , 2019, 20, 237-247.e1.	1.1	118
130	A systematic review on the emerging association between the occurrence of immune-related adverse events and clinical outcomes with checkpoint inhibitors in advanced cancer patients. <i>Seminars in Oncology</i> , 2019, 46, 362-371.	0.8	46
131	Impact of primary tumor location in patients with RAS wild-type metastatic colon cancer treated with first-line chemotherapy plus anti-EGFR or anti-VEGF monoclonal antibodies: a retrospective multicenter study. <i>Journal of Cancer</i> , 2019, 10, 5926-5934.	1.2	24
132	Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice. <i>Journal of Translational Medicine</i> , 2019, 17, 376.	1.8	20
133	Family history of cancer and DNA damage response genes: Two sides of the same coin?. <i>Thoracic Cancer</i> , 2019, 10, 401-401.	0.8	1
134	Immune context characterization and heterogeneity in primary tumors and pulmonary metastases from renal cell carcinoma. <i>Immunotherapy</i> , 2019, 11, 21-35.	1.0	16
135	Predictive value of skeletal muscle mass for immunotherapy with nivolumab in non-small cell lung cancer patients: A hypothesis generator preliminary report. <i>Thoracic Cancer</i> , 2019, 10, 347-351.	0.8	54
136	Family history of cancer as surrogate predictor for immunotherapy with anti-PD-1/PD-L1 immune checkpoint inhibitors: The FAMI-L1 study. <i>Journal of Clinical Oncology</i> , 2019, 37, 2559-2559.	0.8	0
137	The way towards tailored treatment for metastatic renal cancer patients in the omics era: are we getting a transcriptomic compass?. <i>Annals of Translational Medicine</i> , 2019, 7, S190-S190.	0.7	1
138	Multicentric retrospective analysis of platinum-pemetrexed regimens as first-line therapy in non-squamous non-small cell lung cancer patients: A snapshot from clinical practice. <i>Thoracic Cancer</i> , 2018, 9, 241-252.	0.8	6
139	KRAS and 2 rare PI3KCA mutations coexisting in a metastatic colorectal cancer patient with aggressive and resistant disease. <i>Human Pathology</i> , 2018, 74, 178-182.	1.1	5
140	Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: preliminary report of the FAMI-L1 study. <i>Immunotherapy</i> , 2018, 10, 643-655.	1.0	15
141	Where are we with treatment options after first line in small cell lung cancer? A report of two opposite cases treated with CAPTEM regimen and possible perspectives. <i>Journal of Thoracic Disease</i> , 2018, 10, E520-E525.	0.6	0
142	The possible different roles of denosumab in prevention and cure breast cancer bone metastases: A hypothesis generator study from clinical practice. <i>Oncology Letters</i> , 2018, 16, 7195-7203.	0.8	5
143	Immune Checkpoint Inhibitors and Myasthenic Syndromes: A Case Report of a Metastatic Renal Cell Carcinoma Patient Treated With Nivolumab. <i>Journal of Clinical Neuromuscular Disease</i> , 2018, 20, 99-100.	0.3	2
144	Baseline predictive factors for efficacy of anti-PD1 used in first line in melanoma patients: An Italian melanoma intergroup study. <i>Annals of Oncology</i> , 2018, 29, viii449.	0.6	0

#	ARTICLE	IF	CITATIONS
145	Single institution study of correlations between skeletal muscle mass, its density, and clinical outcomes in non-small cell lung cancer patients treated with first-line chemotherapy. <i>Thoracic Cancer</i> , 2018, 9, 1623-1630.	0.8	38
146	“Palliative” or “Supportive”: Is It Just a Matter of Word?. <i>Journal of Palliative Medicine</i> , 2018, 21, 1546-1546.	0.6	0
147	Influenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDia study. <i>Immunotherapy</i> , 2018, 10, 1229-1239.	1.0	38
148	Safe Administration of Ipilimumab, Pembrolizumab, and Nivolumab in a Patient with Metastatic Melanoma, Psoriasis, and a Previous Guillain-Barré Syndrome. <i>Case Reports in Oncological Medicine</i> , 2018, 2018, 1-4.	0.2	6
149	Timed-flat infusion (TFI) 5-fluorouracil with irinotecan and oxaliplatin in pancreatic adenocarcinomas: A single institution experience with Flr/FOx regimen. <i>Annals of Oncology</i> , 2018, 29, v37-v38.	0.6	1
150	Timed-flat infusion of 5-fluorouracil with docetaxel and oxaliplatin as first-line treatment of gastroesophageal adenocarcinoma: A single institution experience with the FD/FOx regimen. <i>Oncology Reports</i> , 2018, 40, 803-812.	1.2	3
151	“Vessels in the Storm”: Searching for Prognostic and Predictive Angiogenic Factors in Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2018, 19, 299.	1.8	29
152	First-line chemotherapy with docetaxel, oxaliplatin, and timed-flat infusion 5-Fluorouracil in metastatic gastro-esophageal adenocarcinomas: The experience with FD/FOx regimen.. <i>Journal of Clinical Oncology</i> , 2018, 36, 178-178.	0.8	0
153	Influenza vaccine indication during anticancer therapy with immune-checkpoint inhibitors: A transversal challenge for patients’ counselling – preliminary analysis of the INVIDia study. <i>Annals of Oncology</i> , 2017, 28, xi17.	0.6	3
154	Topical menthol for treatment of chemotherapy-induced peripheral neuropathy. <i>Indian Journal of Palliative Care</i> , 2017, 23, 350.	1.0	10
155	Oncology Network ASL1 Abruzzo: first year activity bridging the gap between Hospital and Territorial Care. <i>Annals of Oncology</i> , 2016, 27, iv56.	0.6	0
156	Retrospective evaluation of chemotherapy options in non-squamous non-small cell lung cancer (non-Sq NSCLC) patients (pts) unfit for standard platinum-based chemotherapy in clinical practice. <i>Annals of Oncology</i> , 2015, 26, vi88.	0.6	0
157	Prognostic relevance of Hormonal Receptor positive Status in HER2-positive Metastatic Breast Cancer Patients: Retrospective Analysis in Real Life. <i>Annals of Oncology</i> , 2015, 26, vi20.	0.6	0
158	P043 Bevacizumab/paclitaxel as first line therapy for metastatic breast cancer: new schedule in real life. <i>Breast</i> , 2015, 24, S41.	0.9	1
159	Prognostic relevance of KRAS genotype and the prevalent C.35 G > a mutation in metastatic colorectal cancer (MCRC) patients fitting for intensive Flr-B/FOx triplet chemotherapy plus bevacizumab.. <i>Journal of Clinical Oncology</i> , 2014, 32, e14575-e14575.	0.8	0